-$0.59 EPS Expected for FibroGen Inc (NASDAQ:FGEN) This Quarter

Equities analysts expect that FibroGen Inc (NASDAQ:FGEN) will post earnings of ($0.59) per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for FibroGen’s earnings, with the lowest EPS estimate coming in at ($0.72) and the highest estimate coming in at ($0.48). FibroGen reported earnings of ($0.50) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 18%. The firm is expected to report its next earnings results on Thursday, November 14th.

On average, analysts expect that FibroGen will report full year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.69) to ($0.07). For the next financial year, analysts expect that the company will post earnings of ($0.18) per share, with EPS estimates ranging from ($1.75) to $1.41. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow FibroGen.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $1.75. The business had revenue of $191.57 million during the quarter, compared to analyst estimates of $29.03 million. FibroGen had a return on equity of 9.01% and a net margin of 13.90%. FibroGen’s revenue for the quarter was up 335.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.28) earnings per share.

A number of research firms have issued reports on FGEN. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Thursday, October 17th. Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $51.00 price objective for the company in a report on Tuesday, August 13th. ValuEngine downgraded FibroGen from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Mizuho reiterated a “buy” rating and issued a $65.00 price objective on shares of FibroGen in a report on Monday, August 26th. Finally, William Blair reiterated a “hold” rating on shares of FibroGen in a report on Tuesday, July 2nd. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $57.17.

In other news, Director Kalevi Kurkijarvi sold 6,000 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $45.22, for a total transaction of $271,320.00. Following the completion of the transaction, the director now directly owns 34,400 shares in the company, valued at $1,555,568. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Pat Cotroneo sold 3,201 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $41.38, for a total value of $132,457.38. Following the transaction, the chief financial officer now owns 244,432 shares of the company’s stock, valued at $10,114,596.16. The disclosure for this sale can be found here. Insiders have sold 105,156 shares of company stock valued at $4,525,743 over the last 90 days. Corporate insiders own 8.96% of the company’s stock.

Several large investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of FibroGen by 8.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,726 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 378 shares during the last quarter. Doheny Asset Management CA boosted its position in shares of FibroGen by 1.6% during the second quarter. Doheny Asset Management CA now owns 36,471 shares of the biopharmaceutical company’s stock valued at $1,648,000 after buying an additional 586 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in shares of FibroGen by 1.8% during the second quarter. State Board of Administration of Florida Retirement System now owns 40,364 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 720 shares during the last quarter. Zacks Investment Management boosted its position in shares of FibroGen by 2.8% during the second quarter. Zacks Investment Management now owns 26,642 shares of the biopharmaceutical company’s stock valued at $1,204,000 after buying an additional 738 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of FibroGen by 4.1% during the third quarter. Envestnet Asset Management Inc. now owns 22,334 shares of the biopharmaceutical company’s stock valued at $826,000 after buying an additional 881 shares during the last quarter. Hedge funds and other institutional investors own 69.54% of the company’s stock.

FGEN traded down $0.36 during midday trading on Tuesday, hitting $39.63. The stock had a trading volume of 416,300 shares, compared to its average volume of 490,305. The business has a fifty day moving average of $39.15 and a 200 day moving average of $42.66. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.73. The company has a market cap of $3.48 billion, a P/E ratio of -38.48 and a beta of 1.84. FibroGen has a 1 year low of $33.51 and a 1 year high of $61.23.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Article: Understanding each part of a balance sheet

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.